子宫内膜癌从早期到晚期:放射科医生更新
本文综述子宫内膜癌的分子分型、早期与晚期影像表现及当前管理策略,重点介绍晚期新全身治疗。分子分型揭示生物学行为,FIGO分期近期修订,影像正式纳入管理。影像可评估肌层浸润、宫颈间质受累、淋巴结转移和远处转移,对治疗规划至关重要。
要点
- 影像评估肌层浸润、宫颈间质受累、淋巴结转移和远处转移,用于分期与风险分层。
- 分子分型指导晚期子宫内膜癌的靶向治疗和免疫检查点抑制剂选择。
- FIGO分期近期修订,影像被正式纳入子宫内膜癌管理流程。
核心结论
- 影像在子宫内膜癌分期、风险分层和治疗规划中起关键作用,分子分型指导晚期全身治疗选择。
研究设计与样本
- 综述文章,回顾子宫内膜癌分子分型、早期和晚期影像表现及当前管理策略,聚焦晚期新全身治疗。
临床应用与阅片要点
- 阅片需评估肌层浸润深度、宫颈间质是否受累、淋巴结状态及远处转移,以支持FIGO分期和风险分层。
- 结合分子分型信息,晚期患者治疗策略包括手术、放疗和全身治疗,影像报告应为治疗规划提供依据。
局限性
- 本文为综述,未报告原始研究样本量、敏感度、特异度等数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The purpose of this article is to review the current molecular classification of endometrial cancer, the imaging findings in early and advanced disease, and the current management strategies, focusing on the new systemic therapies for advanced EC. In recent years, the management of endometrial cancer has significantly changed. The molecular characterization of endometrial cancer has shed new light into the biologic behavior of this disease, the International Federation of Gynecology and Obstetrics staging system was recently revised, and imaging was formally incorporated in the management of endometrial cancer. Recent genomic analysis of endometrial cancer led to the approval of new molecular-targeted therapies and immune checkpoint inhibitors. Imaging allows assessment of myometrial invasion, cervical stromal extension, lymph node involvement and distant metastases, and has a crucial role for treatment planning. Treatment strategies, which include surgery, radiation and systemic therapies are based on accurate staging and risk stratification.
引用
- Luna C, Balcacer P, Castillo P, et al. Endometrial cancer from early to advanced-stage disease: an update for radiologists. Abdom Radiol (NY). 2021. PMID: 34297164. doi:10.1007/s00261-021-03220-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。